Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
Biotie Therapies Oyj (HEL:BTH) BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE August 8, 2008 at 9.00 a.m.
INTERIM REPORT ON BIOTIE THERAPIES CORP. JANUARY 1 - JUNE 30, 2008
January - June 2008 in brief
- In January Lundbeck acquired the United Kingdom and Ireland rights for nalmefene from Britannia Pharmaceuticals (now part of STADA Group, headquartered in Germany). Following the new agreement Lundbeck has worldwide rights for nalmefene, excluding North America, Mexico, Turkey, and South-Korea.
- In June Biotie announced top-line data from the first-in-man clinical study with its fully human VAP-1 monoclonal antibody. The data from the study support proceeding to clinical studies with repeated doses of the antibody.
- The net loss in January - June stood at EUR 3.3 million (net income in 2007 EUR 1.6 million). Cash flow in January - June from operating activities was EUR -5.8 million (EUR -2.9 million in 2007).
- Revenue for January - June stood at EUR 3.2 million (EUR 5.2 million in 2007) and earnings per share was EUR -0.04 (EUR 0.02 in 2007).
- The company's liquid assets amounted to EUR 23.0 million as at June 30, 2008 (EUR 30.2 million as at June 30, 2007).
Q2/2008 in brief:
- The net loss in April - June stood at EUR 1.3 million (net income in 2007 EUR 2.7 million). Cash flow in April - June from operating activities was EUR -2.5 million (EUR -0.3 million in 2007).
- Revenue for April - June stood at EUR 1.8 million (EUR 4.6 million in 2007) and earnings per share was EUR -0.01 (EUR 0.03 in 2007).
General:
Biotie is a drug development company focusing on dependence disorders, inflammatory diseases and thrombosis.
Drug development projects:
Nalmefene program
In January, Lundbeck acquired the United Kingdom and Ireland rights for nalmefene from Britannia Pharmaceuticals (now part of STADA Group, headquartered in Germany). Following the new agreement Lundbeck has worldwide rights for nalmefene, excluding North America, Mexico, Turkey, and South-Korea.
Biotie-Lundbeck license agreement terms were amended due to Lundbeck acquiring the United Kingdom and Ireland rights. Under the terms of the amended agreement, Biotie is now eligible for up to EUR 82 million in upfront and milestone payments (previously up to EUR 80 million) plus royalty on sales. Of the EUR 82 million, Biotie has already received an execution fee of EUR 12 million from Lundbeck.
To maximise nalmefene's potential in the treatment of alcoholism Biotie and Lundbeck have jointly decided to seek marketing authorisation simultaneously in all 27 EU member states via the centralized procedure. To this end, Lundbeck plans to further strengthen the existing nalmefene registration dossier in its alcoholism indication with additional phase III clinical studies before submitting the marketing authorisation application. The studies are expected to start in 2008. Biotie will participate in financing some of the clinical development costs.
VAP-1 antibody program
Top-line data from the first-in-man study with Biotie's fully human VAP-1 monoclonal antibody BTT-1023 were reported in June 2008. The study was conducted in a clinical pharmacology unit in the United Kingdom and investigated the safety, tolerability and pharmacokinetic characteristics of single intravenous doses of BTT-1023 in healthy volunteer subjects.
A total of 35 subjects, of whom 29 received BTT-1023, were enrolled into the placebo-controlled study. BTT-1023 was generally well tolerated and no serious adverse events were reported in the study. Among the five subjects who received the highest dose, facial flushing was reported by two subjects with accompanying facial oedema in one of the two. These were reported during or shortly after the infusion and are not uncommon events in association with intravenous administration of therapeutic protein drugs. No cytokine release or fever was observed in any subject. All adverse events were fully reversible and required no particular intervention.
The data from the study support proceeding to clinical studies with repeated doses of the antibody. These studies are expected to be carried out in rheumatoid arthritis and psoriasis patients and will aim to establish appropriate dosing regimens for subsequent therapeutic studies and provide initial information on the therapeutic potential of BTT-1023. The studies are expected to start in the end of 2008.
In November 2006, Biotie and Roche signed an option agreement for Biotie's fully human antibody program targeting Vascular Adhesion Protein-1 (VAP-1) in inflammatory diseases.
Under the terms of the agreement, Roche has paid an option initiation fee of EUR 5 million, which grants Roche an exclusive option right to an exclusive, worldwide license agreement for Biotie's fully human antibody targeting VAP-1, excluding Japan, Taiwan, Singapore, New Zealand, and Australia. The initial option right will end upon completion of Phase I. Roche may extend the option right to later development points by paying additional fees. Biotie will retain all rights to the program until a license is granted to Roche.
Inhibiting VAP-1 reduces inflammation by regulating the migration of leukocytes, or white blood cells, to inflamed tissues. Pathological accumulation of white blood cells in tissue is a common feature in many autoimmune diseases, such as rheumatoid arthritis, ulcerative colitis, and psoriasis.
Co-operation with Seikagaku Corporation proceeded as planned.
Pre-clinical programs
Pre-clinical programs (VAP-1 SSAO small molecule inhibitor program and alfa2beta1 integrin inhibitor program) progressed as planned. In the bioheparin program the company continued to look for a partner to finance the future development of the program. To date, partnering efforts have not been successful.
Revenues
Revenue for the reporting period 1.1.-30.6.2008 was EUR 3.2 million. Revenue consisted of periodization of the signing fees of the licensing agreements signed with Seikagaku Corporation in 2003 and with Somaxon Pharmaceuticals in 2004, periodization of the option fee of the option agreement signed with Roche in 2006 as well as periodization of the execution fee of the licensing agreement signed with Lundbeck that entered into force in May 2007. No new milestones or signing fees were received during the reporting period.
Revenue for the period 1.1.-30.6.2007 consisted of periodization of the signing of the licensing agreement signed with Seikagaku Corporation in 2003 and periodization of the signing fee of the licensing agreement in nalmefene project signed with Somaxon Pharmaceuticals in 2004 and periodization of the option fee of the option agreement signed with Roche in 2006 as well as periodization of the execution fee of the licensing agreement signed with Lundbeck that entered into force in May 2007. The revenue was in total EUR 5.2 million. Payment of EUR 2.0 million was received from Lundbeck during the period.
Revenue for April - June 2008 amounted to EUR 1.8 million (EUR 4.6 million in 2007) consisting of periodizations described above.
Financial results
The net loss for the reporting period was EUR 3.3 million (net income in 2007 EUR 1.6 million). Research and development costs for the period amounted to EUR 5.2 million. The corresponding figure for the previous year was EUR 3.5 million.
The net loss in April - June was EUR 1.3 million (net income in April - June 2007 EUR 2.7 million). Research and development costs in the second quarter amounted to EUR 2.8 million (EUR 2.1 million in 2007)
Patent costs have been booked as expenses.
Financing
Biotie's equity ratio was -57.6 % on June 30, 2008 (-25.5 % in 2007). Cash and cash equivalents totaled EUR 23.0 million on June 30, 2008 (EUR 30.2 million in 2007).
The company has invested its liquid assets into bank deposits during the second quarter 2008. Funds are reported in "investments held to maturity". Deposits with maturity less than 3 months are reported in the "cash and cash equivalents". Previously the funds were invested in money market funds.
In January 2008, The Finnish Funding Agency for Technology and Innovation (Tekes) granted EUR 1.7 million additional funding for Biotie Therapies' integrin alpha2beta1 inhibitor program for thrombosis. The R&D funding granted covers drug development costs of the project from July 2007 to December 2009.
The funding granted is in the form of loan and it covers 50 per cent of the costs of the project. The loan will be paid to Biotie against reported realised costs. In order to receive the full amount of granted financing, Biotie must show a total expenditure of EUR 3.4 million in the project.
Shareholder's equity
The shareholders' equity (FAS) of the company is less than half of the company's share capital when capital loans are not included in shareholders' equity. Shareholders' equity and capital loans add up to EUR 14.3 million.
Annual General Meeting was held on March 28, 2008 and considered measures relating to the level of shareholder's equity. It was resolved that no special measures are necessary at this point in time.
Investments and cash flow
The cash flow from operations was EUR -5.8 million (in 2007 EUR -2.9 million The company's investments during the reporting period amounted to EUR 109 thousand (EUR 10 thousand in 2007).
The cash flow from operating activities in April - June was EUR -2.5 million (EUR -0.3 million in 2007). Investments during the second quarter amounted to EUR 92 thousand (EUR 3 thousand in 2007).
Personnel
During the reporting period, the company's personnel was on average 35 (35 in 2007, 39 in 2006) and at the end of the reporting period 36 (33 on June 30, 2007 and 36 on June 30, 2006).
The ten biggest shareholders of Biotie on June 30, 2008
Number of shares % Pequot group: 21,069,624 23.55 - Pequot Healthcare Fund, L.P. (7,765,345) - Pequot Healthcare Offshore Fund, Inc. (5,937,983) - Premium Series PCC Limited (998 490) - Pequot Diversified Master Fund Ltd. (1,201,800) - Pequot Healthcare Institutional Fund, L.P (1 521 406) - Pequot Healthcare Emerging Markets Fund, Ltd. (3,644,600) Finnish Innovation Fund (Sitra) 14,585,350 16.30 Finnish Industry Investment Ltd 6,778,592 7.58 Juha Jouhki and his controlled companies 6,537,672 7.31 - Dreadnought Finance Oy (2,098,416) - Jouhki Juha (1,501,356) - Thominvest Oy (2,937,900) Funds administered by BioFund Management Oy: 2,519,775 2.82 - BioFund Ventures III Ky (2,485,715) - BioFund Ventures I Ky (34,060) Harri Markkula and his controlled company: 1,316,695 1.47 - Tilator Oy (420,700) - Markkula Harri (895,995) Oy H. Kuningas & Co AB 1,058,371 1,18 Oksanen Markku 690,00 0.77 Sij.rahasto ABN Amro small cup 550,000 0.61 Siven Pertti 350,000 0.39 55,456,079 61,99 Nominee registered shares total 6,075,001 6.79 Other shareholders 27,931,780 31.22 Outstanding shares 89,462,860 100.00 The number of the company's own shares held by Biotie Therapies 749,000*) Total 90,211,860
*) The company has in its possession 819.000 of its own shares. Relating to the company's option programs, the company has signed a stock lending agreement with EVLI Bank in January, 2007. Pursuant to this program, the number of the company's own shares in its possession may be temporarily less than 819,000.
Short-term risks and uncertainties
Biotie's strategic risks are related to the technical success of the drug development programs, regulatory issues, the strategic decisions of its commercial partners, ability to obtain and maintain intellectual property rights for its products, validity of its patents, launch of competitive products and the development of the sales of its products and availability of capital. For example, even though the commercialisation and collaboration agreements on the company's product development projects have been concluded, there can be no assurance that the contracting partner will act in accordance with the agreement, the authorities will approve the product under development or the approved product will be commercialised. The development and success of the company's products depends on third parties.
The operational risks include dependency of key personnel, assets and dependency on partners' decisions.
Future outlook
- Lundbeck is expected to start additional phase III studies with nalmefene in its alcohol indication in 2008.
- Due to Biotie having two programs in the clinical development phase the operating costs are expected to increase to a somewhat higher level for 2008 than in 2007.
- Revenue in 2008 is estimated to be approximately EUR 5 to 6 million and consists of periodization of already received payments based on established revenue recognition principles. The company is not expecting new milestone payments based on existing agreements in 2008.
IFRS and Accounting principles
The interim report has been prepared in accordance with IAS 34, Interim Financial Reporting. Biotie has applied the same accounting principles as in the closing of year 2007.
This interim report is unaudited.
Biotie's interim report for January - September will be published on October 24, 2008.
In Turku, August 8, 2008
Biotie Therapies Corp.
Board of Directors
For further information, please contact: Timo Veromaa, President and CEO, Biotie Therapies Corp. tel. +358 2 274 8901, e-mail: timo.veromaa@biotie.com
www.biotie.com
Distribution: OMX Nordic Exchange Helsinki Main Media
APPENDICES TO THE FINANCIAL STATEMENTS
Income statement Balance sheet Statement of changes in shareholders' equity Cash flow statement Key figures
Research and -2,797 -2,074 -5,200 -3,549 -9,053 development expenses General and -424 -366 -899 -963 -1,655 administrative expenses Other operating 61 426 120 684 1,044 income Operating -1,322 2,592 -2,820 1,383 -1,769 profit/loss
Non-current assets Intangible assets 720 774 747 Property, plant and equipment 370 84 332 Financial assets at fair value 0 20,000 14,938 through profit or loss 1,090 20,858 16,017
Current assets Accounts receivables and other 726 1,031 753 receivables Investments held to maturity 17,500 0 0 Financial assets at fair value through 0 9,302 13,000 profit or loss Cash and cash equivalents 5,504 936 305 23,730 11,270 14,058
Total 24,820 32,128 30,075
Equity and liabilities
Shareholders' equity
Share capital 19,850 19,850 19,850 Reserve for invested unrestricted 980 980 980 equity Retained earnings -31,832 -30,619 -30,220 Net income/loss -3,302 1,583 -1,726 Shareholders' equity total -14,304 -8,207 -11,117
Current liabilities Provisions 20 16 20 Current financial liabilities 143 15 104 Accounts payable and other current 5,791 2,864 7,353 debts 5,955 2,895 7,477 Liabilities total 39,124 40,335 41,192
Total 24,820 32,128 30,075
STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY
Attributable to equity holders of the parent company
EUR 1,000 Shares Share Reserve Own Retained Share- (1000 Capital For Shares Earnings holders' pcs) invested equity Un- total restricted equity Balance at 89,531 19,850 0 -15 -30,641 -10,807 1.1.2007 Net income/loss 1,583 1,583 for the period Options granted 38 38 Share subscription 450 841 841 with Convertible capital loans Share subscription 231 139 139 with Option rights 681 0 980 0 1,621 2,600 BALANCE AT 90,212 19,850 980 -15 -29,020 -8,207 30.6.2007 Net income/loss -3,309 -3,309 for the period Options granted 399 399 0 0 0 0 -2,910 -2,910 BALANCE AT 90,212 19,850 980 -15 -31,930 -11,117 31.12.2007 Net income/loss -3,302 -3,302 for the period Options granted 115 115 0 0 0 0 -3,187 -3,187 BALANCE AT 90,212 19,850 980 -15 -35,117 -14,304 30.6.2008
Net income/loss -3,302 1,583 -1,726 Adjustments: Non-cash transactions 240 99 443 Addition/disposal due to 0 -517 -644 revaluation of financial assets at fair value through profit or loss Interest expenses and other 717 401 817 financial expenses Interest income -235 -601 -216 Taxes 0 0 0 Change in working capital: Change in accounts receivables and 245 -448 -190 other receivables Change in accounts payable and -3,499 -3,507 -3,799 other liabilities Change in mandatory provisions -10 8 10 Interests paid -2 -10 -40 Interests received 31 85 57 Taxes paid 0 0 0 Net cash from operating activities -5,815 -2,908 -5,288
Cash flow from investing activities Change in financial assets at fair value through profit or loss Additions 0 -3,000 -4,500 Disposals 27,685 2,154 5,280 Change in investments held to maturity Additions -22,500 0 0 Disposals 5,000 0 0 Investments to tangible assets -27 -10 -23 Net cash used in investing 10,158 -856 757 activities
Cash flow from financing activities Payments from share issue 0 139 139 Proceeds from borrowings 888 689 874 Repayment of loans 0 0 -40 Repayment of lease -32 -12 -23 commitments Net cash from financing 856 815 950 activities
Net increase (+) or decrease (-) 5,199 -2,949 -3,581 in cash and cash equivalents Cash and cash equivalents in the 305 3,886 3,886 beginning of the period Cash and cash equivalents in the 5,504 936 305 end of the period
KEY FIGURES 1.1.- 1.1.- 1.1.- 30.6.2008 30.6.2007 31.12.2007 EUR 1,000 6 months 6 months 12 months Business development Revenues 3,159 5,210 7,895 Personnel on average 35 35 36 Personnel at the end of period 36 33 37 Research and development costs 5,200 3,549 9,053 Capital expenditure 109 10 287
Profitability Operating profit/loss -2,820 1,383 -1,769 as percentage of revenues, % -89.3 26.5 -22.4 Profit/loss before taxes -3,302 1,583 -1,726 as percentage of revenues, % -104.5 30.4 -21.9
Balance sheet Cash and cash equivalents 23,004 30,239 28,243 Shareholders equity -14,304 -8,207 -11,117 Balance sheet total 24,820 32,128 30,075
Financial ratios Return on equity, % - - - Return on capital employed, % -45.0 28.4 -7.2 Equity ratio, % -57.6 -25.5 -37.0 Gearing, % -11.7 83.8 40.8
Per share data Earnings per share (EPS) basic & -0.04 0.02 -0.02 diluted, EUR Shareholders'equity per share, EUR -0.16 -0.09 -0.12 Dividend per share, EUR Pay-out ratio, % Effective dividend yield, % P/E-ratio
Share price Lowest share price, EUR 0.50 0.85 0.75 Highest share price, EUR 0.94 1.18 1.22 Average share price, EUR 0.70 0.99 0.98 End of period share price, EUR 0.53 0.91 0.76 Market capitalization 47.8 82.1 68.6 at the end of period MEUR Trading of shares Number of shares traded 7,103,973 25,749,500 35,093,743 As percentage of all 7.9 28.5 38.9 Adjusted weighted average 90,211,860 89,661,658 90,003,192 Number of shares during the period Adjusted number of shares 90,211,860 90,211,860 90,211,860 at the end of the period
Related party transactions
There have not been material changes within the related party transactions in 2008.
Formulas for the Calculation of the Financial Ratios
Return on equity, % Profit (loss) before extraordinary items - taxes --------------------------------------------------------------- x 100 Shareholders' equity
Return on capital employed, % Profit (loss) before taxes + interest expenses and other financial expenses --------------------------------------------------------------- x 100 Balance sheet total - non-interest bearing liabilities
Equity ratio, % Shareholders' equity --------------------------------------------------------------- x 100 Balance sheet total - advanced received
Gearing, % Interest bearing liabilities - cash and cash equivalents -------------------------------------------------------------- x 100 Shareholders' equity Earnings per share (EPS) Profit before extraordinary items, appropriations and taxes - minority interest - taxes ------------------------------------------------------------------ Adjusted average number of outstanding shares during the period
Shareholders' equity per share Shareholders' equity ------------------------------------------------------------------ Adjusted average number of outstanding shares at the end of the period
